New PET scan tracer could sharpen view of melanoma treatment response
NCT ID NCT07215182
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether a new radioactive tracer, [68Ga]Ga-FAPI-46, can improve how doctors evaluate response to immunotherapy in patients with stage IV melanoma. Twenty participants will receive two experimental PET/CT scans—one before starting immunotherapy and one after three months—along with blood samples. The results will be compared with standard FDG PET/CT scans to see if the new tracer provides clearer information about tumor changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- [68Ga]Ga-FAPI-46 (an experimental imaging tracer)
- What this could lead to
- If successful, this could provide a more accurate way to measure how well immunotherapy is working in advanced melanoma patients, potentially guiding treatment decisions.
- What could go wrong
- This is a small, early-phase study (20 participants) focused on imaging, not treatment. The tracer may not prove more useful than current standard scans, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA STAGE IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Herlev Universityhospital
RECRUITINGHerlev, Capital Region, 2730, Denmark
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Rigshospitalet
RECRUITINGCopenhagen, Ca, 2100, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.